Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2008 1
2011 2
2012 1
2013 1
2014 1
2015 2
2016 1
2017 1
2019 2
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH; DIPAK-1 Investigators. van Aerts RMM, et al. Gastroenterology. 2019 Aug;157(2):481-491.e7. doi: 10.1053/j.gastro.2019.04.018. Epub 2019 Apr 22. Gastroenterology. 2019. PMID: 31022403 Clinical Trial.
We made use of data from an open-label, randomized trial to determine the effects of lanreotide on height-adjusted liver volume (hTLV) and combined height-adjusted liver and kidney volume (hTLKV) in patients with ADPKD. ...CONCLUSIONS: In this subanalysis of …
We made use of data from an open-label, randomized trial to determine the effects of lanreotide on height-adjusted liver volum …
A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.
Strosberg JR, Cheema A, Kvols LK. Strosberg JR, et al. Cancer Control. 2011 Apr;18(2):127-37. doi: 10.1177/107327481101800207. Cancer Control. 2011. PMID: 21451455 Free article. Review.
BACKGROUND: Treatment options for metastatic gastroenteropancreatic neuroendocrine tumors (NETs) have evolved in recent years. The somatostatin analogs octreotide and lanreotide have long been used for management of symptoms such as flushing and diarrhea associated with ho …
BACKGROUND: Treatment options for metastatic gastroenteropancreatic neuroendocrine tumors (NETs) have evolved in recent years. The somatosta …
Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Wetzels JF, Drenth JP. Gevers TJ, et al. Liver Int. 2015 May;35(5):1607-14. doi: 10.1111/liv.12726. Epub 2014 Dec 1. Liver Int. 2015. PMID: 25369108
Chronic renal dysfunction in ADPKD may affect treatment efficacy of lanreotide and possibly enhances risk for adverse events. The aim of this open-label clinical trial (RESOLVE trial) was to assess the efficacy of 6-month lanreotide treatment, 120 mg, subcutaneously …
Chronic renal dysfunction in ADPKD may affect treatment efficacy of lanreotide and possibly enhances risk for adverse events. The aim …
Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data.
Temmerman F, Gevers T, Ho TA, Vanslembrouck R, Coudyzer W, van Pelt J, Bammens B, Pirson Y, Drenth JP, Nevens F. Temmerman F, et al. Aliment Pharmacol Ther. 2013 Aug;38(4):397-406. doi: 10.1111/apt.12384. Epub 2013 Jun 25. Aliment Pharmacol Ther. 2013. PMID: 23799922 Free article. Clinical Trial.
BACKGROUND: Long-acting lanreotide (LAN) 120 mg every 4 weeks reduces liver volume (LV) in patients with polycystic liver diseases (PCLD). ...Based on ROC analysis, a reduction of 120 mL in LV has a positive predictive value of 64% for improving symptoms (ROC …
BACKGROUND: Long-acting lanreotide (LAN) 120 mg every 4 weeks reduces liver volume (LV) in patients with polycystic liver
Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease.
Temmerman F, Chen F, Libbrecht L, Vander Elst I, Windmolders P, Feng Y, Ni Y, De Smedt H, Nevens F, van Pelt J. Temmerman F, et al. World J Gastroenterol. 2017 Aug 14;23(30):5499-5507. doi: 10.3748/wjg.v23.i30.5499. World J Gastroenterol. 2017. PMID: 28852309 Free PMC article.
Animals received: controls (n = 14), lanreotide (LAN: 3 mg/kg per 2 wk) (n = 10) or everolimus (EVR: 1 mg/kg per day) (n = 7). LV was measured at week 16, 24, 28. At week 28, all rats were sacrificed and liver tissue was harvested. Fibrosis was evaluated using quant …
Animals received: controls (n = 14), lanreotide (LAN: 3 mg/kg per 2 wk) (n = 10) or everolimus (EVR: 1 mg/kg per day) (n = 7). LV was …
Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
Gevers TJ, Nevens F, Torres VE, Hogan MC, Drenth JP. Gevers TJ, et al. Liver Int. 2016 Apr;36(4):595-602. doi: 10.1111/liv.12986. Epub 2015 Nov 9. Liver Int. 2016. PMID: 26481454 Free PMC article.
We performed uni- and multivariate linear regression analysis with preselected patient, disease and drug variables to identify independent predictors of response, defined as per cent change in liver or kidney volume (in ADPKD subgroup). All analyses were adjusted fo …
We performed uni- and multivariate linear regression analysis with preselected patient, disease and drug variables to identify indepe …
The long-term outcome of patients with polycystic liver disease treated with lanreotide.
Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, van Oijen MG, Coudyzer W, Hoffmann AL, Dekker HM, de Man RA, van Keimpema L, Drenth JP. Chrispijn M, et al. Aliment Pharmacol Ther. 2012 Jan;35(2):266-74. doi: 10.1111/j.1365-2036.2011.04923.x. Epub 2011 Nov 24. Aliment Pharmacol Ther. 2012. PMID: 22111942 Free article. Clinical Trial.
Somatostatin analogues, such as lanreotide, reduce polycystic liver volume. AIM: To establish long-term outcome and safety of lanreotide. ...Stopping results in recurrence of polycystic liver growth. This suggests that continuous use of lanreotide
Somatostatin analogues, such as lanreotide, reduce polycystic liver volume. AIM: To establish long-term outcome and safety of …
Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H, Shimatsu A, Okayama A, Sato T. Yamaguchi H, et al. Endocr J. 2020 Feb 28;67(2):201-210. doi: 10.1507/endocrj.EJ19-0266. Epub 2019 Nov 13. Endocr J. 2020. PMID: 31723069 Free article.
Mean dose of pegvisomant was 10.6 6.1 mg/day in the entire treatment period (except for initial loading dose). The incidence of adverse drug reactions was 35.6% (89/250). No new safety concerns related to long-term treatment were observed. The major investigation items of …
Mean dose of pegvisomant was 10.6 6.1 mg/day in the entire treatment period (except for initial loading dose). The incidence of adverse d
[Hepatic encephalopathy after injection of lanreotide, a somatostatin analog].
Robin E, Lebrec D, Hammel P, Bernades P, Ruszniewski P. Robin E, et al. Gastroenterol Clin Biol. 1996;20(11):1014-6. Gastroenterol Clin Biol. 1996. PMID: 9119171 French.
We report one case of hepatic encephalopathy following the administration of a somatostatin analogue (lanreotide) in a patient with a pancreatic endocrine tumor and liver metastases. ...The diagnosis of hepatic encephalopathy relied upon a positive re-challenge test …
We report one case of hepatic encephalopathy following the administration of a somatostatin analogue (lanreotide) in a patient with a …